I propose to take Questions Nos. 463, 469, 474, 486, 488, 499 and 508 together.
Firstly, I would like to acknowledge the incredibly important role of Radiation Therapists in the provision of cancer services in this country.
I am glad that the independent review of the Radiation Therapist profession has been finalised. This strategic review considered important issues such as organisation structure, career development in line with Health and Social Care Professional Frameworks, strategic workforce planning and recruitment and retention strategies.
This review has published 16 recommendations which aim to help and support the Radiation Therapy profession into the future. These recommendations are now being examined by my Department regarding implementation.
Since 2017, there has been additional investment of over €456m in cancer services, including €81m on cancer prevention, screening, and treatment; €316m on cancer medicines; and €59m on cancer research grants through the Health Research Board. Seven years into the ten-year National Cancer Strategy, 40 of the 52 recommendations are implemented and the remainder are being progressed.
Capital funding of over €140m has been used to provide state of the art radiation oncology facilities in Galway and Cork, to update cancer infrastructure in chemotherapy wards and lab facilities for the benefit of patients, and as investment in the new National Cervical Screening Laboratory.
New development funding has enabled the recruitment of more than 670 staff to our national cancer services since 2017, including an additional 200 nursing staff, 100 consultants, and 180 health and social care professionals in designated cancer centres. This means that our national cancer services have been strengthened, that more patients are receiving treatment, and that waiting times to access treatment are reduced.
New treatments are now available in Ireland for the first time, including tailored anti-cancer therapies, and new radiotherapy treatments. 10% of radiation therapy patients are now receiving new treatments such as SABR which offer more targeted treatment which can help reduce side-effects.